Amgen's Vectibix wins expanded colorectal cancer indications in Europe
This article was originally published in Scrip
Executive Summary
Amgen has won the European Commission's blessing to market the firm's anti-epidermal growth factor receptor (EGFR) inhibitor Vectibix (panitumumab) in the European Union for the expanded indications of treating patients with wild-type KRAS metastatic colorectal cancer (mCRC) as a first-line therapy in combination with FOLFOX (folinic acid, fluorouracil and oxaliplatin) and as a second-line treatment in combination with FOLFIRI (fololinic acid, fluorouracil and irinotecan) in patients who have received first-line fluoropyrimidine-based chemotherapy, excluding irinotecan.